AIMLogo.jpg
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
April 29, 2024 08:55 ET | AIM ImmunoTech Inc.
OCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the...
LOGO-01.png
Burning Rock Publishes 2023 Annual Report on Form 20-F
April 29, 2024 03:30 ET | Burning Rock Biotech Limited
Burning Rock Publishes 2023 Annual Report on Form 20-F
cgoncology_cover.jpg
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024 08:00 ET | CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
Cardiff.jpg
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
April 25, 2024 16:05 ET | Cardiff Oncology, Inc.
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a...
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 25, 2024 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
cgoncology_cover.jpg
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024 10:00 ET | CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
NOVARTIS logo.jpg
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
April 23, 2024 13:42 ET | Novartis Pharma AG
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic...
cmi_logo.png
[Latest] Global 3D Cell Culture Market Size/Share Worth USD 4.6 Billion by 2033 at a 11.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 18, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Cell Culture Market Size, Trends and Insights By Product (Scaffolds Based 3d...
Colorado State Unive
Colorado State University Global’s Teaching and Learning Programs Impact K-12 Education in Colorado
April 18, 2024 10:42 ET | Colorado State University Global
Aurora, Colo., April 18, 2024 (GLOBE NEWSWIRE) -- Colorado State University Global (CSU Global), the CSU System’s fully online university, ranked by U.S. News & World Report as a top provider of...
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 18, 2024 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...